Patrick A. Brown

10.6k total citations · 2 hit papers
160 papers, 5.7k citations indexed

About

Patrick A. Brown is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Molecular Biology. According to data from OpenAlex, Patrick A. Brown has authored 160 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Public Health, Environmental and Occupational Health, 95 papers in Hematology and 46 papers in Molecular Biology. Recurrent topics in Patrick A. Brown's work include Acute Lymphoblastic Leukemia research (95 papers), Acute Myeloid Leukemia Research (73 papers) and Chronic Myeloid Leukemia Treatments (33 papers). Patrick A. Brown is often cited by papers focused on Acute Lymphoblastic Leukemia research (95 papers), Acute Myeloid Leukemia Research (73 papers) and Chronic Myeloid Leukemia Treatments (33 papers). Patrick A. Brown collaborates with scholars based in United States, Canada and France. Patrick A. Brown's co-authors include Donald Small, Edward Allan R. Sison, Stacy Cooper, Daniel Magoon, Mark J. Levis, Rachel E. Rau, Emily McIntyre, Peter Valent, Mark Wunderlich and Jun Qi and has published in prestigious journals such as Nature, JAMA and Journal of Biological Chemistry.

In The Last Decade

Patrick A. Brown

156 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

2011 1.4k citations Edward Allan R. Sison, Daniel Magoon et al. profile →
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

2021 207 citations Patrick A. Brown, Lingyun Ji et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick A. Brown United States	38	2.9k	2.8k	1.7k	1.3k	758	160	5.7k
Jan Starý Czechia	42	1.5k 0.5×	3.1k 1.1×	2.4k 1.4×	1.0k 0.8×	931 1.2×	255	5.0k
Nicolas Boissel France	42	2.0k 0.7×	3.6k 1.3×	1.9k 1.1×	1.5k 1.1×	466 0.6×	200	6.1k
Michael Dworzak Austria	45	1.2k 0.4×	3.6k 1.3×	3.0k 1.7×	1.2k 0.9×	1.0k 1.4×	189	5.8k
Michael Rytting United States	31	1.1k 0.4×	2.1k 0.7×	2.1k 1.2×	1.3k 1.0×	804 1.1×	96	4.2k
Elisabeth R. van Wering Netherlands	40	1.4k 0.5×	2.4k 0.8×	3.1k 1.8×	653 0.5×	1.3k 1.7×	101	4.6k
Peter Westervelt United States	39	1.8k 0.6×	3.2k 1.2×	721 0.4×	1.4k 1.0×	256 0.3×	195	5.7k
Gritta Janka‐Schaub Germany	33	1.1k 0.4×	2.1k 0.8×	2.1k 1.2×	737 0.6×	1.1k 1.4×	66	5.1k
Martin Höglund Sweden	37	1.5k 0.5×	3.4k 1.2×	1.1k 0.6×	1.2k 0.9×	193 0.3×	134	5.1k
E Archimbaud France	34	2.3k 0.8×	3.3k 1.2×	1.1k 0.6×	1.4k 1.0×	194 0.3×	124	5.1k
William Blum United States	43	2.5k 0.9×	2.7k 1.0×	667 0.4×	1.3k 1.0×	199 0.3×	188	5.6k

Countries citing papers authored by Patrick A. Brown

Since Specialization

Citations

This map shows the geographic impact of Patrick A. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Brown more than expected).

Fields of papers citing papers by Patrick A. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick A. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Brown. The network helps show where Patrick A. Brown may publish in the future.

Co-authorship network of co-authors of Patrick A. Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick A. Brown. A scholar is included among the top collaborators of Patrick A. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick A. Brown. Patrick A. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrison, Claire, Ruben A. Mesa, Moshe Talpaz, et al.. (2024). Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Haematology. 11(10). e729–e740. 11 indexed citations

Verma, Anupam, Yueh‐Yun Chi, Jemily Malvar, et al.. (2024). Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers. 16(3). 496–496. 6 indexed citations

Hogan, Laura, Patrick A. Brown, Lingyun Ji, et al.. (2023). Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. Journal of Clinical Oncology. 41(25). 4118–4129. 33 indexed citations

Jeyaraju, Danny V., Sheida Hayati, Jia Wang, et al.. (2023). Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial. Blood. 142(Supplement 1). 4526–4526. 1 indexed citations

Brown, Patrick A., Lingyun Ji, Xinxin Xu, et al.. (2021). A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. Blood. 138(Supplement 1). 363–363. 7 indexed citations

Koldobskiy, Michael A., Garrett Jenkinson, Jordi Abante, et al.. (2021). Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. Nature Biomedical Engineering. 5(4). 360–376. 13 indexed citations

Baruchel, André, Patrick A. Brown, Carmelo Rizzari, et al.. (2020). Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open. 5(5). e000977–e000977. 23 indexed citations

Brown, Patrick A., Lingyun Ji, Xinxin Xu, et al.. (2019). A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. Blood. 134(Supplement_2). LBA–1. 51 indexed citations

Wayne, Alan S., Van Huynh, Rupert Handgretinger, et al.. (2017). ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Annals of Oncology. 28. v360–v361. 7 indexed citations

10.

Cooper, Todd M., Elena Eckroth, Jemily Malvar, et al.. (2016). A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical Cancer Research. 22(16). 4014–4022. 56 indexed citations

11.

Sison, Edward Allan R., Daniel Magoon, Li Li, et al.. (2015). POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget. 6(31). 30902–30918. 29 indexed citations

12.

Hayley, S., Bao Nguyen, Amy S. Duffield, et al.. (2014). FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia. Cancer Research. 74(18). 5206–5217. 25 indexed citations

13.

Matheny, Christina, Michael C. Wei, Michael C. Bassik, et al.. (2013). Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. Chemistry & Biology. 20(11). 1352–1363. 57 indexed citations

14.

Raetz, Elizabeth A., D. Morrison, Paul S. Gaynon, et al.. (2013). A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL). Journal of Pediatric Hematology/Oncology. 36(6). 458–463. 34 indexed citations

15.

Nguyen, Bao, et al.. (2012). Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 27(1). 48–55. 79 indexed citations

16.

d’Amore, Francesco, Thomas Relander, Esa Jantunen, et al.. (2009). Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group. Lund University Publications (Lund University). 20 indexed citations

17.

Brown, Patrick A. & Franklin O. Smith. (2008). Molecularly Targeted Therapies for Pediatric Acute Myeloid Leukemia. Pediatric Drugs. 10(2). 85–92. 6 indexed citations

18.

Tappin, Simon, Patrick A. Brown, & Luca Ferasin. (2007). An intestinal neuroendocrine tumour associated with paroxysmal ventricular tachycardia and melaena in a 10‐year‐old boxer. Journal of Small Animal Practice. 49(1). 33–37. 7 indexed citations

19.

Brown, Patrick A.. (2006). Answers to key questions about childhood leukemia--for the generalist. Contemporary pediatrics. 23(3). 81–98. 1 indexed citations

20.

Brown, Patrick A. & Donald Small. (2004). FLT3 Inhibitors. European Journal of Cancer. 40(5). 707–721. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact